Integrity Is Divided Into Key Interlinking Knowledge Areas:

• DRUGS & BIOLOGICS: Essential chemical and pharmacological information, and the development status of bioactive compounds in the drug pipeline.
• EXPERIMENTAL PHARMACOLOGY: Data from experimental studies that delineate drug/receptor and enzyme/target cell interactions.
• PHARMACOKINETICS/METABOLISM: Data from experimental and clinical studies that delineate the absorption, distribution, metabolism and excretion (ADME) profile of a drug.
• ORGANIC SYNTHESIS: Routes of synthesis (schemes, intermediates, reagents, end products) for drugs currently on the market or in development.
• DISEASE BRIEFINGS: Dynamic executive summaries on the current status of and future trends in drug therapy.
• GENOMICS: Use relationships between genes and diseases to gain insight into underlying biological mechanisms and identify potential new drug targets.
• TARGETS & PATHWAYS: Find out about precedented targets and explore their role in pathological pathways.
• CLINICAL STUDIES: Information on clinical trials of drugs currently under study or in use in humans.

Supplement and enhance your searches with fully integrated information on:

• COMPANIES AND RESEARCH INSTITUTES: Essential information on public and private companies, academic centers and research institutions active in the field of pharmaceuticals and biotechnology.
• LITERATURE: References to current biomedical literature, abstracts and proceedings from congresses and symposia and company communications.
• PATENTS: References to the most recent patent literature reflecting drug research activity throughout the world.

Overview

The Biomarkers Module of Thomson Reuters Integrity^SM provides a wealth of reliable, high-quality, continually updated information supporting biomarker research at every stage of drug R&D including:

• Target identification
• Proof of mechanism
• Proof of concept
• Treatment/safety monitoring
• Outcome measurement

The Biomarkers Module is the first biomarker database to provide standardized terminology and to classify biomarkers reliably into lifecycle phases and disciplines. It is designed to help you make better, more informed decisions as you strive to improve cost efficiency, predict and minimise risk and avoid late stage attrition.

Integrity allows you to contextualize and assess the relative importance of each biomarker by exploring the associated drugs, targets and genes.

Biomarkers Module Development

What can Biomarkers do for you?

• Discovery biologists
  Helping you to:
  • Learn the biology of the disease you’re working on, and to understand the current research situation regarding biomarkers in your therapy area.
  • Choose the biomarker that will give early indications as to whether modifying a potential target has a positive outcome on the disease process.
• Pre-clinical scientists
  Helping you to:
  • Find the biomarkers that show the effects of your compound on the disease state.
  • Select suitable biomarkers for use in safety and efficacy studies to give early indication of toxicity and proof of concept.
• Clinical researchers
  Helping you to:
  • Find the population that will respond best to the particular treatment.
  • Know which biomarkers to use to improve the design and efficiency of your studies, and improve your probability of success.
• Translational researchers
  Helping you to:
  • Connect experimental research and clinical studies for pivotal insights.
  • Assign the right biomarker to the right project as early as possible enabling you to maximize the benefit of using biomarkers in a development project.

The Biomarkers Module is also available as an XML feed for your in-house informatics solutions.

We look forward to meeting you meeting you the following events in 2011:

• Biomarker World Congress
  Loews, Philadelphia, USA
  May 2-4, 2011